Clinical Trial Update: A Single-arm, Phase Ⅱ Clinical Trial of Anlotinib Hydrochloride Combined With Irinotecan or Docetaxel for Second Line Treatment of Nonsensitive Relapsed Small-cell Lung Cancer [Phase 2]

View source ↗

Summary

A single-arm Phase 2 trial evaluating anlotinib hydrochloride in combination with irinotecan or docetaxel for second-line treatment of relapsed small-cell lung …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Anlotinib hydrochloride (anlotinib)
• DOCETAXEL (DOCETAXEL)
• Irinotecan (Irinotecan)

Snippet

Sponsor: First People's Hospital of Hangzhou | Conditions: Relapsed Small Cell Lung Cancer, Anlotinib | Phase 2 | Status: UNKNOWN